Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Pharmaceutical Technology
Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for DMD.
pharminent
September 11, 2026 (Last updated: September 16, 2026)
Pharmaceutical Technology
Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for DMD.